Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

Next Previous
Trial Profile

An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COM 701 (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms MAIA-ovarian; sub-trial 1
  • Sponsors Compugen

Most Recent Events

  • 22 Sep 2026 According to a Compugen media release, the company will host a virtual key opinion leader (KOL) event on Monday, October 5, 2026 at 8:00 AM in event Dr. Yeku will preview the randomized MAIA-ovarian adaptive platform trial design of COM701.
  • 03 Aug 2026 According to a Compugen media release, the company anticipates the interim analysis with median progression-free survival data by the first quarter of 2027.
  • 18 Jun 2026 According to a Compugen Media Release, a poster of this trial were presented at the ESMO Gynaecological Cancers Congress 2026, in Copenhagen, Denmark with initial data expected by Q1 of 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top